{"id":"NCT00022672","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer","officialTitle":"A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-01","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2003-01-27","resultsPosted":"2013-06-13","lastUpdate":"2013-06-13"},"enrollment":208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"trastuzumab (Herceptin®)","otherNames":["Herceptin®"]},{"type":"DRUG","name":"anastrazole (Arimidex®)","otherNames":["Arimidex®"]}],"arms":[{"label":"trastuzumab + anastrozole","type":"EXPERIMENTAL"},{"label":"anastrozole","type":"ACTIVE_COMPARATOR"}],"summary":"This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"24 Months, End of Study (Up to 5 years)","effectByArm":[{"arm":"Trastuzumab + Anastrozole","deltaMin":4.8,"sd":null},{"arm":"Anastrozole","deltaMin":2.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":132,"countries":["United States","Australia","Brazil","Bulgaria","Canada","China","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Lithuania","Mexico","Netherlands","Norway","Poland","Russia","South Africa","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":103},"commonTop":["Diarrhoea","Fatigue","Vomiting","Pyrexia","Arthralgia"]}}